Innova Captab Limited (NSE:INNOVACAP)

Market Cap	38.42B -8.7%
Revenue (ttm)	14.97B +25.6%
Net Income	1.32B +3.9%
EPS	23.13 -8.2%
Shares Out	57.22M
PE Ratio	29.02
Forward PE	21.77
Dividend	4.00 (0.60%)
Ex-Dividend Date	Jan 30, 2026

Volume	110,893
Average Volume	30,748
Open	703.20
Previous Close	711.55
Day's Range	663.90 - 712.35
52-Week Range	622.00 - 1,020.70
Beta	-0.50
RSI	45.16
Earnings Date	May 21, 2026

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinoly...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,600
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: INNOVACAP

Financial Performance

In fiscal year 2025, Innova Captab's revenue was 12.44 billion, an increase of 15.02% compared to the previous year's 10.81 billion. Earnings were 1.28 billion, an increase of 35.95%.